About GLP One

GLP One is an independent editorial site covering GLP-1 medications — semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda, Victoza), dulaglutide (Trulicity), exenatide, and emerging agents. We write for adults considering or already using GLP-1 medications who want clear, evidence-based information.

Editorial mission

We started GLP One because the public conversation about GLP-1 drugs is loud, fast, and often shallow. Brand-name social media posts focus on weight loss "before and after" photos. Anti-pharma posts focus on side effects. Both leave readers without the information they actually need: what these drugs are, who they help, who they harm, how to access them legally, and what they cost.

Our goal is to be the most useful, honest English-language information site on GLP-1 medications. That means we publish the safety information you need even when it conflicts with the marketing of brands we link to, and we publish the access information you need even when it complicates the picture for advocacy groups on either side.

Editorial standards

Every article on GLP One is researched against the following primary sources, in order of authority:

1. Current FDA-approved labeling for the medication being discussed (Mounjaro, Ozempic, Wegovy, Rybelsus, Saxenda, Victoza, Trulicity, Byetta, Bydureon, Zepbound).
2. Peer-reviewed clinical trials in major journals (NEJM, The Lancet, JAMA, Diabetes Care, Lancet Diabetes & Endocrinology), with primary attention to the STEP trial series (semaglutide for weight management), SURMOUNT series (tirzepatide), SCALE series (liraglutide), SUSTAIN series (semaglutide for diabetes), REWIND (dulaglutide), and SELECT (semaglutide cardiovascular outcomes).
3. Statements and guidelines from the US Food and Drug Administration, American Diabetes Association, American Association of Clinical Endocrinology, Endocrine Society, and the Obesity Society.
4. Pharmacy compounding regulations as set out in sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

Fact-checking and review

Articles are written by the GLP One editorial team and reviewed against the sources above. The "Last reviewed" date at the top of each article reflects the most recent material review. We update articles when:

• New FDA labeling is issued.
• A new trial reports primary results.
• Drug shortage status changes (this affects what compounding pharmacies may legally prepare).
• Pricing data changes meaningfully.
• A reader brings a correction we can verify.

Our long-term plan is to engage a licensed clinical pharmacist or registered nurse with weight management or endocrinology experience to provide periodic content review and to be named on this page. When that engagement is in place, we will update this section with the reviewer's name, credentials, and license information.

How we make money

GLP One earns commissions through affiliate partnerships with telehealth services that connect patients with licensed clinicians. We do not accept payment from pharmaceutical manufacturers. We do not accept payment to soften safety information. See our Affiliate Disclosure.

What we are not

GLP One is not a healthcare provider. We do not diagnose, prescribe, or treat. We do not have access to your medical records. We do not collect personal medical information. If you click an outbound link to a telehealth partner, that partner — not GLP One — is responsible for the clinical relationship, prescribing decisions, and any medications dispensed.

Corrections

If you find a factual error on the Site, email hello@glpone.us.com. We take corrections seriously and update articles transparently.

Contact

General inquiries: hello@glpone.us.com